Dass-167 [2021] Jun 2026

The DASS-167 is a self-report questionnaire consisting of 167 items, divided into three subscales:

Based on the promising preclinical data, DASS-167 has entered clinical development for the treatment of COVID-19. A Phase 1 clinical trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of DASS-167 in healthy volunteers. The results of the study showed that DASS-167 was well-tolerated, with no evidence of significant adverse effects.

The DASS-167, also known as the Depression Anxiety Stress Scales, is a self-report questionnaire consisting of 21 items. The test is divided into three subscales: Depression (DASS-D), Anxiety (DASS-A), and Stress (DASS-S). Each subscale contains 7 items, which are rated on a 4-point Likert scale. The DASS-167 is designed to assess the severity of emotional symptoms in individuals, providing a quick and efficient way to screen for depression, anxiety, and stress. DASS-167

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a devastating impact on global health and economies. The rapid spread of the virus has necessitated the development of effective therapeutic agents to combat the disease. In recent years, researchers have been actively engaged in the discovery and development of small molecule inhibitors targeting various stages of the SARS-CoV-2 life cycle. One such promising compound is the DASS-167, a novel and potent inhibitor of SARS-CoV-2.

Assuming DASS-167 refers to a 167-item version of the DASS assessment tool (although it's not a widely recognized or standard version), I will provide an overview of the DASS and its applications. The DASS-167 is a self-report questionnaire consisting of

The DASS-167, also known as the Depression Anxiety Stress Scales, is a self-report questionnaire developed by Peter Lovibond and Sydney Lovibond in 1995. The 167-item version is one of several iterations of the DASS, with the original version consisting of 42 items. The DASS-167 aims to assess the severity of depression, anxiety, and stress in individuals.

The "DASS" prefix is a serial code from the production company (or a distributor using that prefix). The company is known for releasing content that ranges from standard scenarios to more unique or "extreme" themes. The "167" denotes this title as the 167th release in its specific series. The DASS-167, also known as the Depression Anxiety

The DASS has been widely used in research and clinical settings to assess the severity of depression, anxiety, and stress in individuals. The tool has been translated into several languages and has demonstrated good reliability and validity across different populations.